Injectable drugs for weight management.

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic disease research

Background:

• Obesity management requires a multifaceted approach, integrating behavioral changes and professional monitoring.
• Injectable medications are increasingly utilized for weight management.
• Key drug classes include glucagon-like peptide-1 (GLP-1) receptor agonists and dual GIP/GLP-1 receptor agonists.

Purpose of the Study:

• To review the mechanisms of action for current injectable weight management medications.
• To discuss the efficacy and potential adverse effects associated with these therapies.
• To highlight the importance of long-term adherence and patient monitoring.

Main Methods:

• Review of current literature on GLP-1 receptor agonists and GIP/GLP-1 receptor agonists for weight management.
• Analysis of drug mechanisms, including appetite regulation and metabolic effects.
• Examination of reported adverse events and clinical considerations.

Main Results:

• These injectable drugs mimic incretin hormones (GLP-1, GIP) to reduce appetite, alter food perception, slow gastric emptying, and enhance insulin secretion.
• Weight regain is common upon cessation, indicating a need for sustained treatment.
• Common side effects are gastrointestinal; rarer but serious risks include gallstones and pancreatitis.

Conclusions:

• Injectable incretin mimetics offer a significant tool in obesity management when combined with lifestyle interventions.
• Long-term therapy is typically required, necessitating ongoing patient monitoring for efficacy and safety.
• Careful consideration of potential adverse effects and patient selection is crucial, including monitoring for mental health impacts and misuse.